Also, Zydus has introduced two AI-enabled CGM devices in India.
The global healthcare artificial intelligence (AI) landscape continues to expand, with key developments across the United States, South Korea, India, and Thailand highlighting growing adoption in diagnostics, chronic care, and regulatory frameworks.
South Korea-based Neurophet has entered into a strategic partnership with the Alzheimer's Network for Treatment and Diagnostics (ALZ-NET) in the United States to deploy AI-powered imaging software for Alzheimer’s disease monitoring.
The collaboration will enable participating sites within ALZ-NET to utilise Neurophet’s US Food and Drug Administration (FDA)-cleared imaging analysis tools to detect and monitor amyloid-related imaging abnormalities, a key factor in Alzheimer’s treatment management.
ALZ-NET, sponsored by the Alzheimer's Association and operated by the American College of Radiology, aggregates real-world clinical and imaging data from patients undergoing emerging Alzheimer’s therapies to standardise care practices and strengthen evidence-based treatment approaches.
In a separate development, another South Korean firm, JLK, has secured US FDA 510(k) clearance for its non-contrast CT-based stroke analysis software, JLK-NCCT.
The solution enables rapid analysis of non-contrast CT scans to detect intracerebral haemorrhage and identify suspected large-vessel occlusion, improving early triage in emergency settings without the need for CT angiography. This marks another regulatory milestone for JLK, following multiple FDA clearances last year for its stroke-related AI tools. The software has also received approval in Japan.
Meanwhile in India, Zydus Lifesciences has launched an AI-enabled continuous glucose monitoring (CGM) platform aimed at enhancing chronic disease management.
The system, featuring Diasens and GlucoLive devices, delivers glucose readings to smartphones every three minutes without requiring manual scanning. Integrated AI analytics track glucose trends, generate alerts, and support clinical decision-making through a remote monitoring dashboard available on the GoodFlip app, developed in collaboration with Digicare Health Solutions.
The platform is designed for patients with diabetes, chronic kidney disease, and those undergoing post-transplant care, where continuous glycaemic monitoring is critical.
On the regulatory front, Ministry of Higher Education, Science, Research and Innovation in Thailand has initiated a framework to establish safety and quality standards for AI-powered medical devices.
The initiative includes agreements with key national agencies such as the National Science and Technology Development Agency, Thai Food and Drug Administration, and National Electronics and Computer Technology Center.
The framework aims to develop robust testing, validation, and regulatory infrastructure for AI-based medical software, aligning with international standards such as ISO/IEC 17025, while ensuring clinical accuracy, safety, and interoperability.
These developments collectively signal a strengthening global push toward integrating AI into healthcare delivery, with parallel progress in innovation, clinical deployment, and regulatory oversight.